<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00454519</url>
  </required_header>
  <id_info>
    <org_study_id>WUCC-0701</org_study_id>
    <nct_id>NCT00454519</nct_id>
  </id_info>
  <brief_title>Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis</brief_title>
  <acronym>IPHC</acronym>
  <official_title>Cytoreductive Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy for the Treatment of Peritoneal Carcinomatosis From Gastrointestinal Cancer: an Open Label, Randomized, Prospective, Phase 2 Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NPO Organization to Support Peritoneal Dissemination Treatment</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kishiwada Tokushukai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kusatsu General Hopital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ikeda Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuhan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVES:

        -  Determine response and survival of patients with peritoneal carcinomatosis treated with
           cytoreductive surgery plus intraoperative peritoneal hyperthermic chemotherapy with
           cisplatin and mitomycin

        -  Assess the quality of life of patients treated with this regimen.

      OUTLINE: Patients are randomized into IPHC group and control group. In the former group, the
      patients undergo cytoreductive surgery plus intraoperative hyperthermic peritoneal perfusion
      with cisplatin and mitomycin over 60 minutes. Patients in the control group just underwent
      routine cytoreductive surgery.

      All patients in both groups receive the standard conventional chemotherapy after surgery.

      Quality of life is assessed at study initiation, at 1, 3, 6 months. Patients are followed at
      4 weeks, every 3 months for 1 year, and then every 6 months for up to 3 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DISEASE CHARACTERISTICS:

        -  Histologically confirmed peritoneal carcinomatosis with the following histologies:

        -  Primary peritoneal mesothelioma

        -  Adenocarcinoma of gastrointestinal tract origin

        -  Confined to peritoneal cavity

        -  Tumor mass could be debulked to less than 2.5 cm in diameter per tumor deposit

        -  Must not have failed prior intraperitoneal platinum therapy

        -  Treatment failure is defined as radiographic evidence of disease progression on 2
           consecutive CT scans within 3 months after therapy

      PATIENT CHARACTERISTICS:

      Age:

      - 20 to 70 years old

      Performance status:

      - KPS&gt;50

      Life expectancy:

      - More than 8 weeks

      Hematopoietic:

        -  WBC at least 3,500/mm^3

        -  Platelet count at least 80,000/mm^3

      Hepatic:

        -  Bilirubin no greater than 2 times upper limit of normal (ULN)

        -  AST and ALT no greater than 2 times ULN

        -  Liver enzymes no greater than 2 times ULN

      Renal:

      - Creatinine no greater than 1.5 mg/dL

      Cardiovascular:

        -  No significant irreversible cardiac ischemia

        -  No significant changes in ECG recording

      Pulmonary:

        -  FEV_1 at least 1.2 liters

        -  Maximum voluntary ventilation at least 50% expected

      Other:

        -  Not pregnant or nursing

        -  Negative pregnancy test

        -  No concurrent medical problems that would preclude surgery
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2007</start_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival time</measure>
    <time_frame>from operation to death due to cancer recurrence</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>perioperative morbidity and mortality</measure>
    <time_frame>Within 30 days postoperation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Stomach Neoplasms</condition>
  <condition>Colorectal Neoplasms</condition>
  <condition>Neoplasm Metastasis</condition>
  <condition>Mesothelioma</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cytoreductive surgery, IPHC, cisplatin 20 mg/m2/L, Mitomycin C 4 mg/m2/L, postoperative chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cytoreductive surgery alone, postoperative chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cytoreductive surgery</intervention_name>
    <description>the whole abdominal-pelvic cavity is explored and maximal cytoreductive surgery is performed to remove visible tumor burden as much as possible.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin</intervention_name>
    <description>Immediately after the cytoreductive surgery, cisplatin and mitomycin C dissolved in 12,000 ml of normal saline heated to 42 degrees celsius is infused into the abdominal cavity for a sustained hyperthermic intraperitoneal chemotherapy for 60 to 90 minutes.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>HIPEC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gastric cancer or colorectal cancer with peritoneal carcinomatosis

          -  Gastric cancer or colorectal cancer with malignant ascites

          -  Karnofsky Performance Scale(KPS)&gt;50

        Exclusion Criteria:

          -  Age less than 20 years old, or beyond 70 years old

          -  Any lung metastasis, liver metastasis, or prominent retroperitoneal lymph node
             metastasis

          -  Bilirubin greater than 3 times upper limit of normal (ULN)

          -  AST and ALT greater than 5 times ULN

          -  Liver enzymes greater than 3 times ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan Li, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Center of Wuhan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yonemura Yutaka, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NPO Organization to Support Peritoneal Dissemination Treatment</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan Li, M.D., Ph.D</last_name>
    <phone>+86-27-62337478</phone>
    <email>liyansd2@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Center of Wuhan University &amp; Department of Oncology, Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Li, M.D., Ph.D</last_name>
      <phone>+86-27-67813152</phone>
      <phone_ext>3152</phone_ext>
      <email>liyansd2@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yonemura Yutaka, M.D., Ph.D</last_name>
      <phone>+81-072-433-2131</phone>
      <email>y.yonemura@coda.ocn.ne.jp</email>
    </contact_backup>
    <investigator>
      <last_name>Guo-Liang Yang, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fu-Lin Cheng, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yan Li, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mao-Hui Feng, M.D., Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shibo Masaya, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Yang XJ, Li Y, al-shammaa Hassan AH, Yang GL, Liu SY, Lu YL, Zhang JW, Yonemura Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases. Ann Surg Oncol. 2009 Feb;16(2):345-51. doi: 10.1245/s10434-008-0226-2. Epub 2008 Nov 19.</citation>
    <PMID>19018599</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2007</study_first_submitted>
  <study_first_submitted_qc>March 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2007</study_first_posted>
  <last_update_submitted>February 12, 2009</last_update_submitted>
  <last_update_submitted_qc>February 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Yan Li, M.D., Ph.D</name_title>
    <organization>Cancer Center of Wuhan University</organization>
  </responsible_party>
  <keyword>peritoneal carcinomatosis</keyword>
  <keyword>cisplatin</keyword>
  <keyword>mitomycin</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

